for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vaxart Inc

VXRT.OQ

Latest Trade

0.56USD

Change

-0.06(-9.19%)

Volume

175,611

Today's Range

0.56

 - 

0.62

52 Week Range

0.56

 - 

7.60

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.62
Open
0.62
Volume
175,611
3M AVG Volume
4.20
Today's High
0.62
Today's Low
0.56
52 Week High
7.60
52 Week Low
0.56
Shares Out (MIL)
15.79
Market Cap (MIL)
10.10
Forward P/E
-0.83
Dividend (Yield %)
--

Latest Developments

More

Vaxart Qtrly Loss Per Share $0.39

Vaxart Enters Into Research Collaboration With Janssen To Evaluate Oral Universal Influenza Vaccine

Vaxart Reports Qtrly Loss Per Share $0.18

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vaxart Inc

Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.

Industry

Biotechnology & Drugs

Contact Info

395 Oyster Point Blvd Ste 405

+1.650.5503500

http://aviragentherapeutics.com/

Executive Leadership

Wouter W. Latour

President, Chief Executive Officer, Principal Financial Officer, Director

Margaret A Echerd

Principal Accounting Officer

Sean N Tucker

Chief Scientific Officer

David Taylor

Chief Medical Officer

Michael J. Finney

Director

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.34
Price To Book (MRQ)
0.64
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
17.94
LT Debt To Equity (MRQ)
7.42
Return on Investment (TTM)
-53.61
Return on Equity (TTM)
-43.35

Latest News

BRIEF-Vaxart Appoints Dr. David Taylor As Chief Medical Officer

* VAXART APPOINTS DR. DAVID TAYLOR AS CHIEF MEDICAL OFFICER Source text for Eikon: Further company coverage:

BRIEF-Vaxart Announces $5 Mln Inavir Revenue Milestone

* VAXART - NOTIFIED BY DAIICHI SANKYO CO THAT SALES OF INAVIR EXCEEDED ¥20 BILLION IN FISCAL YEAR 2017, TRIGGERING A $5 MILLION MILESTONE PAYMENT TO CO

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up